Genetic and clinical characteristics according to TP53 alteration
| . | TP53unaltered . | TP53altered . | P . |
|---|---|---|---|
| Cytogenetics | n = 62 | n = 157 | |
| ≥ 5 aberrations | 38 (61%) | 139 (89%) | < .0001 |
| Marker chromosomes | 29 (47%) | 114 (73%) | .0005 |
| −5/5q− | 20 (32%) | 124 (79%) | < .0001 |
| −7/7q− | 25 (40%) | 81 (52%) | .14 |
| −5/5q− and −7/7q− | 12 (19%) | 70 (45%) | .0006 |
| −20/20q− | 8 (13%) | 44 (28%) | .02 |
| MK | 34 (55%) | 137 (87%) | < .0001 |
| Array-based genomics | n = 70 | n = 164 | |
| Total no. of losses (mean ± SD) | 4.00 ± 4.88 | 9.54 ± 7.49 | < .0001 |
| Total no. of gains (mean ± SD) | 1.94 ± 1.92 | 3.91 ± 3.80 | < .0001 |
| Total no. of amplifications (mean ± SD) | 0.21 ± 0.83 | 0.84 ± 1.31 | .0002 |
| Total no. of genomic aberrations (mean ± SD) | 6.16 ± 5.53 | 14.30 ± 9.41 | < .0001 |
| −3/3p− | 7 (10%) | 47 (29%) | .002 |
| −5/5q− | 20 (29%) | 127 (77%) | < .0001 |
| −7/7q− | 26 (37%) | 97 (59%) | .003 |
| −5/5q− and −7/7q− | 13 (19%) | 87 (53%) | < .0001 |
| −11/11q− | 13 (19%) | 22 (13%) | .32 |
| −12/12p− | 13 (19%) | 52 (32%) | .06 |
| −16/16q− | 5 (7%) | 61 (37%) | < .0001 |
| −18/18q− | 9 (13%) | 56 (34%) | .0008 |
| −20/20q− | 8 (11%) | 47 (29%) | .004 |
| +1/+1p | 3 (4%) | 34 (21%) | .001 |
| +8/+8q | 21 (30%) | 46 (28%) | .75 |
| +9/+9p | 11 (16%) | 17 (10%) | .27 |
| +11/+11q | 7 (10%) | 54 (33%) | .0002 |
| +13/+13q | 3 (4%) | 26 (16%) | .02 |
| +19/+19p | 3 (4%) | 22 (13%) | .04 |
| +21/+21q | 7 (10%) | 32 (20%) | .09 |
| +22/+22q | 6 (9%) | 27 (16%) | .15 |
| amp(8)(q24) | 4 (6%) | 4 (2%) | .24 |
| amp(11)(q13∼25) | 0 (0%) | 22 (13%) | .0004 |
| amp(21)(q22) | 3 (4%) | 19 (12%) | .09 |
| Molecular MK | 16 (23%) | 59 (36%) | .07 |
| Molecular genetics | n = 50 | n = 99 | |
| FLT3-ITD positive | 3 (6%) | 1 (1%) | .11 |
| FLT3-TKD mutation | 3 (6%) | 1 (1%) | .11 |
| NPM1 mutation | 3 (6%) | 0 (0%) | .04 |
| Clinical data | n = 52 | n = 103 | |
| Sex (male/female) | 26 (50%)/26 (50%) | 54 (52%)/49 (48%) | .87 |
| Median age, y | 54 | 61 | .002 |
| AML history | |||
| De novo | 36 (69%) | 76 (74%) | .57 |
| Secondary | 6 (12%) | 9 (9%) | .58 |
| Therapy-related | 9 (17%) | 16 (16%) | .82 |
| Median WBC, × 106/L | 12.9 | 6.5 | .18 |
| Median platelet count, × 106/L | 48 | 41 | .46 |
| Median hemoglobin, g/dL | 9.1 | 8.9 | .38 |
| Median BM blast count, % | 78 | 65 | .04 |
| Median PB blast count, % | 45 | 30 | .18 |
| Median LDH serum level, U/L | 391 | 438 | .25 |
| Response | n = 52 | n = 103 | |
| CR after induction therapy | 26 (50%) | 29 (28%) | .01 |
| RD after induction therapy | 18 (35%) | 53 (51%) | .06 |
| Outcome | n = 52 | n = 103 | |
| OS | |||
| Median, mo | 10.97 | 4.14 | < .0001 |
| 3-y survival rate, % | 28 | 3 | |
| EFS | |||
| Median, mo | 1.94 | 1.12 | .0007 |
| 3-y survival rate, % | 13 | 1 | |
| RFS | |||
| Median, mo | 12.16 | 6.51 | .01 |
| 3-y survival rate, % | 30 | 7 |
| . | TP53unaltered . | TP53altered . | P . |
|---|---|---|---|
| Cytogenetics | n = 62 | n = 157 | |
| ≥ 5 aberrations | 38 (61%) | 139 (89%) | < .0001 |
| Marker chromosomes | 29 (47%) | 114 (73%) | .0005 |
| −5/5q− | 20 (32%) | 124 (79%) | < .0001 |
| −7/7q− | 25 (40%) | 81 (52%) | .14 |
| −5/5q− and −7/7q− | 12 (19%) | 70 (45%) | .0006 |
| −20/20q− | 8 (13%) | 44 (28%) | .02 |
| MK | 34 (55%) | 137 (87%) | < .0001 |
| Array-based genomics | n = 70 | n = 164 | |
| Total no. of losses (mean ± SD) | 4.00 ± 4.88 | 9.54 ± 7.49 | < .0001 |
| Total no. of gains (mean ± SD) | 1.94 ± 1.92 | 3.91 ± 3.80 | < .0001 |
| Total no. of amplifications (mean ± SD) | 0.21 ± 0.83 | 0.84 ± 1.31 | .0002 |
| Total no. of genomic aberrations (mean ± SD) | 6.16 ± 5.53 | 14.30 ± 9.41 | < .0001 |
| −3/3p− | 7 (10%) | 47 (29%) | .002 |
| −5/5q− | 20 (29%) | 127 (77%) | < .0001 |
| −7/7q− | 26 (37%) | 97 (59%) | .003 |
| −5/5q− and −7/7q− | 13 (19%) | 87 (53%) | < .0001 |
| −11/11q− | 13 (19%) | 22 (13%) | .32 |
| −12/12p− | 13 (19%) | 52 (32%) | .06 |
| −16/16q− | 5 (7%) | 61 (37%) | < .0001 |
| −18/18q− | 9 (13%) | 56 (34%) | .0008 |
| −20/20q− | 8 (11%) | 47 (29%) | .004 |
| +1/+1p | 3 (4%) | 34 (21%) | .001 |
| +8/+8q | 21 (30%) | 46 (28%) | .75 |
| +9/+9p | 11 (16%) | 17 (10%) | .27 |
| +11/+11q | 7 (10%) | 54 (33%) | .0002 |
| +13/+13q | 3 (4%) | 26 (16%) | .02 |
| +19/+19p | 3 (4%) | 22 (13%) | .04 |
| +21/+21q | 7 (10%) | 32 (20%) | .09 |
| +22/+22q | 6 (9%) | 27 (16%) | .15 |
| amp(8)(q24) | 4 (6%) | 4 (2%) | .24 |
| amp(11)(q13∼25) | 0 (0%) | 22 (13%) | .0004 |
| amp(21)(q22) | 3 (4%) | 19 (12%) | .09 |
| Molecular MK | 16 (23%) | 59 (36%) | .07 |
| Molecular genetics | n = 50 | n = 99 | |
| FLT3-ITD positive | 3 (6%) | 1 (1%) | .11 |
| FLT3-TKD mutation | 3 (6%) | 1 (1%) | .11 |
| NPM1 mutation | 3 (6%) | 0 (0%) | .04 |
| Clinical data | n = 52 | n = 103 | |
| Sex (male/female) | 26 (50%)/26 (50%) | 54 (52%)/49 (48%) | .87 |
| Median age, y | 54 | 61 | .002 |
| AML history | |||
| De novo | 36 (69%) | 76 (74%) | .57 |
| Secondary | 6 (12%) | 9 (9%) | .58 |
| Therapy-related | 9 (17%) | 16 (16%) | .82 |
| Median WBC, × 106/L | 12.9 | 6.5 | .18 |
| Median platelet count, × 106/L | 48 | 41 | .46 |
| Median hemoglobin, g/dL | 9.1 | 8.9 | .38 |
| Median BM blast count, % | 78 | 65 | .04 |
| Median PB blast count, % | 45 | 30 | .18 |
| Median LDH serum level, U/L | 391 | 438 | .25 |
| Response | n = 52 | n = 103 | |
| CR after induction therapy | 26 (50%) | 29 (28%) | .01 |
| RD after induction therapy | 18 (35%) | 53 (51%) | .06 |
| Outcome | n = 52 | n = 103 | |
| OS | |||
| Median, mo | 10.97 | 4.14 | < .0001 |
| 3-y survival rate, % | 28 | 3 | |
| EFS | |||
| Median, mo | 1.94 | 1.12 | .0007 |
| 3-y survival rate, % | 13 | 1 | |
| RFS | |||
| Median, mo | 12.16 | 6.51 | .01 |
| 3-y survival rate, % | 30 | 7 |
ITD indicates internal tandem duplication; and TKD, tyrosine kinase domain.